These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25798877)

  • 1. Aberrant expression of the CHFR prophase checkpoint gene in human B-cell non-Hodgkin lymphoma.
    Song A; Ye J; Zhang K; Yu H; Gao Y; Wang H; Sun L; Xing X; Yang K; Zhao M
    Leuk Res; 2015 May; 39(5):536-43. PubMed ID: 25798877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers.
    Mizuno K; Osada H; Konishi H; Tatematsu Y; Yatabe Y; Mitsudomi T; Fujii Y; Takahashi T
    Oncogene; 2002 Apr; 21(15):2328-33. PubMed ID: 11948416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers.
    Kang HC; Kim IJ; Park JH; Shin Y; Park HW; Ku JL; Yang HK; Lee KU; Choe KJ; Park JG
    Oncol Rep; 2004 Jul; 12(1):129-33. PubMed ID: 15201973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer.
    Satoh A; Toyota M; Itoh F; Sasaki Y; Suzuki H; Ogi K; Kikuchi T; Mita H; Yamashita T; Kojima T; Kusano M; Fujita M; Hosokawa M; Endo T; Tokino T; Imai K
    Cancer Res; 2003 Dec; 63(24):8606-13. PubMed ID: 14695171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant methylation of the CHFR gene in advanced hepatocellular carcinoma.
    Sakai M; Hibi K; Kanazumi N; Nomoto S; Inoue S; Takeda S; Nakao A
    Hepatogastroenterology; 2005; 52(66):1854-7. PubMed ID: 16334792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer.
    Yanokura M; Banno K; Kawaguchi M; Hirao N; Hirasawa A; Susumu N; Tsukazaki K; Aoki D
    Oncol Rep; 2007 Jan; 17(1):41-8. PubMed ID: 17143476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer.
    Tokunaga E; Oki E; Nishida K; Koga T; Yoshida R; Ikeda K; Kojima A; Egashira A; Morita M; Kakeji Y; Maehara Y
    Breast Cancer Res Treat; 2006 May; 97(2):199-203. PubMed ID: 16502017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHFR-associated early G2/M checkpoint defects in breast cancer cells.
    Erson AE; Petty EM
    Mol Carcinog; 2004 Jan; 39(1):26-33. PubMed ID: 14694445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation.
    Cheung HW; Ching YP; Nicholls JM; Ling MT; Wong YC; Hui N; Cheung A; Tsao SW; Wang Q; Yeun PW; Lo KW; Jin DY; Wang X
    Mol Carcinog; 2005 Aug; 43(4):237-45. PubMed ID: 15937956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHFR aberrant methylation involves a subset of human lung adenocarcinoma associated with poor clinical outcomes.
    Koga T; Takeshita M; Ijichi K; Yano T; Maehara Y; Sueishi K
    Hum Pathol; 2013 Jul; 44(7):1382-90. PubMed ID: 23415374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic inactivation of CHFR in human tumors.
    Toyota M; Sasaki Y; Satoh A; Ogi K; Kikuchi T; Suzuki H; Mita H; Tanaka N; Itoh F; Issa JP; Jair KW; Schuebel KE; Imai K; Tokino T
    Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7818-23. PubMed ID: 12810945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
    Banno K; Yanokura M; Kawaguchi M; Kuwabara Y; Akiyoshi J; Kobayashi Y; Iwata T; Hirasawa A; Fujii T; Susumu N; Tsukazaki K; Aoki D
    Int J Oncol; 2007 Oct; 31(4):713-20. PubMed ID: 17786301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant methylation of the CHFR gene in digestive tract cancer.
    Morioka Y; Hibi K; Sakai M; Koike M; Fujiwara M; Kodera Y; Ito K; Nakao A
    Anticancer Res; 2006; 26(3A):1791-5. PubMed ID: 16827108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression.
    Privette LM; González ME; Ding L; Kleer CG; Petty EM
    Cancer Res; 2007 Jul; 67(13):6064-74. PubMed ID: 17596595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer.
    Koga Y; Kitajima Y; Miyoshi A; Sato K; Sato S; Miyazaki K
    J Gastroenterol; 2006 Feb; 41(2):133-9. PubMed ID: 16568372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter methylation of CHFR gene in gastric carcinoma tissues detected using two methods.
    Cheng ZD; Hu SL; Sun YB; Xu WP; Shen G; Kong XY
    Chin J Cancer; 2010 Feb; 29(2):163-6. PubMed ID: 20109344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer.
    Shibata Y; Haruki N; Kuwabara Y; Ishiguro H; Shinoda N; Sato A; Kimura M; Koyama H; Toyama T; Nishiwaki T; Kudo J; Terashita Y; Konishi S; Sugiura H; Fujii Y
    Carcinogenesis; 2002 Oct; 23(10):1695-9. PubMed ID: 12376479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer.
    Corn PG; Summers MK; Fogt F; Virmani AK; Gazdar AF; Halazonetis TD; El-Deiry WS
    Carcinogenesis; 2003 Jan; 24(1):47-51. PubMed ID: 12538348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHFR hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.
    Gao L; Liu F; Zhang H; Sun J; Ma Y
    Genes Chromosomes Cancer; 2016 Feb; 55(2):158-68. PubMed ID: 26542416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer.
    Yoshida K; Hamai Y; Suzuki T; Sanada Y; Oue N; Yasui W
    Anticancer Res; 2006; 26(1A):49-54. PubMed ID: 16475678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.